title: [Comparison of Postoperative Analgesic Effects between 0.25% Levobupivacaine and 0.5% Levobupivacaine Local Instillation in Inguinal Hernia Repair].
abstract: BACKGROUND
  We compared retrospectively postoperative analgesia of two concentrations of levobupivacaine by local spraying in radical repair of inguinal hernia.
  
  
  METHODS
  Subjects were patients undergoing unilateral inguinal hernia repair under general anesthesia in five months. The group receiving 0.25% levobupivacaine was Group 0.25%LEV, while the group receiving 0.5% levobupivacaine was Group 0.5%LEV. Levobupivacaine was sprayed over the wound before the external oblique muscle aponeurosis suture and the skin suture. The analgesic effect was evaluated for pain at rest (the time of departure operation room, 1, 2, 3, 4 hours later and the next day) and when walking (4 hours later and the next day) by using the Numerical Rating Scale. We also assessed the use of rescue dose.
  
  
  RESULTS
  Group 0.25% LEV included 29 cases and Group 0.5% LEV included 34 cases, and there were no significant differences in demographic data. There were no significant differences between the two groups with the pain at rest and walking. Rescue dose was used in 3 cases of the both groups.
  
  
  CONCLUSIONS
  In inguinal hernia repair, it is possible that local spraying of 0.25% levobupivacaine exerts the same effect as 0.5% levobupivacaine.
authors.forename: Takahiro
authors.initials: T
authors.lastname: Kato
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sasaki
mesh_terms: D000779:Anesthetics, Local / Q000008:administration & dosage*; D002045:Bupivacaine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006552:Hernia, Inguinal / Q000601:surgery; D006801:Humans; D000077554:Levobupivacaine; D008297:Male; D008875:Middle Aged; D010149:Postoperative Pain / Q000188:drug therapy*; D011184:Postoperative Period; D012189:Retrospective Studies
chemical_list: D000779:Anesthetics, Local; D000077554:Levobupivacaine; D002045:Bupivacaine